Graeme Milligan

List of Publications by Year
in descending order

472 papers	27,004 citations	4960 84 h-index	10734 138 g-index
485 all docs	485 docs citations	485 times ranked	18536 citing authors

#	Article	IF	Citations
1	Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.	27.8	739
2	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. Journal of Neuroscience, 2006, 26, 2080-2087.	3.6	553
3	G Proteinâ€“Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacological Reviews, 2014, 66, 413-434.	16.0	497
4	Tailoring cAMP-signalling responses through isoform multiplicity. Trends in Biochemical Sciences, 1997, 22, 217-224.	7.5	417
5	G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology. Molecular Pharmacology, 2004, 66, 1-7.	2.3	366
6	Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 2009, 5, 131-134.	8.0	349
7	Heterotrimeric G-proteins: a short history. British Journal of Pharmacology, 2006, 147, S46-S55.	5.4	347
8	G-Proteinâ€“Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. Circulation, 2005, 111, 1806-1813.	1.6	346
9	The dynamic role of palmitoylation in signal transduction. Trends in Biochemical Sciences, 1995, 20, 181-186.	7.5	312
10	G proteinâ€coupled receptor heteroâ€dimerization: contribution to pharmacology and function. British Journal of Pharmacology, 2009, 158, 5-14.	5.4	303
11	International Union of Pharmacology. LXXI. Free Fatty Acid Receptors FFA1, -2, and -3: Pharmacology and Pathophysiological Functions. Pharmacological Reviews, 2008, 60, 405-417.	16.0	293
12	The experimental power of FR900359 to study Gq-regulated biological processes. Nature Communications, 2015, 6, 10156.	12.8	282
13	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. Pharmacological Reviews, 2007, 59, 5-13.	16.0	274
14	Inverse agonism: pharmacological curiosity or potential therapeutic strategy?. Trends in Pharmacological Sciences, 1995, 16, 10-13.	8.7	270
15	Abolition of the expression of inhibitory guanine nucleotide regulatory protein Gi activity in diabetes. Nature, 1987, 327, 229-232.	27.8	248
16	Deconvolution of complex G proteinâ€“coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nature Biotechnology, 2010, 28, 943-949.	17.5	246
17	Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes. Pharmacological Reviews, 2010, 62, 701-725.	16.0	246
18	Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective: TABLE 1. Molecular Pharmacology, 2003, 64, 1271-1276.	2.3	239

#	Article	IF	Citations
19	Receptor for the Pain Modulatory Neuropeptides FF and AF Is an Orphan G Protein-coupled Receptor. Journal of Biological Chemistry, 2000, 275, 25965-25971.	3.4	233
20	Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and Bioluminescence Resonance Energy Transfer. Journal of Biological Chemistry, 2001, 276, 14092-14099.	3.4	227
21	Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production. Cell Reports, 2020, 30, 2934-2947.e6.	6.4	221
22	Complex Pharmacology of Free Fatty Acid Receptors. Chemical Reviews, 2017, 117, 67-110.	47.7	209
23	The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. Molecular Pharmacology, 2016, 89, 388-398.	2.3	206
24	Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS Journal, 2005, 272, 2914-2925.	4.7	203
25	A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor. Analytical Biochemistry, 1997, 252, 115-126.	2.4	201
26	Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochemical Journal, 2002, 365, 429-440.	3.7	197
27	Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function. Journal of Biological Chemistry, 2006, 281, 38812-38824.	3.4	197
28	Metabolism meets immunity: The role of free fatty acid receptors in the immune system. Biochemical Pharmacology, 2016, 114, 3-13.	4.4	197
29	Î²-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature, 2016, 531, 661-664.	27.8	190
30	Principles: Extending the utility of [35S]GTPÎ³S binding assays. Trends in Pharmacological Sciences, 2003, 24, 87-90.	8.7	184
31	Î²-Arrestin 1 and GÎ±q/11 Coordinately Activate RhoA and Stress Fiber Formation following Receptor Stimulation. Journal of Biological Chemistry, 2005, 280, 8041-8050.	3.4	180
32	Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production. ISME Journal, 2018, 12, 610-622.	9.8	173
33	The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism. Molecular Pharmacology, 2013, 84, 710-725.	2.3	172
34	Antibodies to the GTP binding protein, Go, antagonize noradrenaline-induced calcium current inhibition in NG108-15 hybrid cells. Neuron, 1989, 3, 177-182.	8.1	165
35	Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends in Pharmacological Sciences, 2007, 28, 615-620.	8.7	162
36	Purification of heterotrimeric GTP-binding proteins from brain: identification of a novel form of Go. Biochemistry, 1988, 27, 7085-7090.	2.5	160

#	Article	IF	Citations
37	Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2258-2262.	7.1	157
38	The Î±1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function. Molecular Pharmacology, 2007, 71, 1015-1029.	2.3	154
39	Applying label-free dynamic mass redistribution technology to frame signaling of G proteinâ€“coupled receptors noninvasively in living cells. Nature Protocols, 2011, 6, 1748-1760.	12.0	154
40	Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 2009, 10, 139-147.	16.2	151
41	Mechanisms of multifunctional signalling by G protein-linked receptors. Trends in Pharmacological Sciences, 1993, 14, 239-244.	8.7	150
42	G protein-coupled receptor dimerisation: Molecular basis and relevance to function. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 825-835.	2.6	149
43	Derivation of Endothelial Cells From Human Embryonic Stem Cells by Directed Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1389-1397.	2.4	147
44	Discovery of a Potent and Selective GPR120 Agonist. Journal of Medicinal Chemistry, 2012, 55, 4511-4515.	6.4	145
45	Targeted Elimination of G Proteins and Arrestins Defines Their Specific Contributions to Both Intensity and Duration of G Protein-coupled Receptor Signaling. Journal of Biological Chemistry, 2016, 291, 27147-27159.	3.4	143
46	Immunological Analysis of Glucose Transporters Expressed in Different Regions of the Rat Brain and Central Nervous System. Biochemical and Biophysical Research Communications, 1993, 192, 1297-1302.	2.1	138
47	Inverse agonism and the regulation of receptor number. Trends in Pharmacological Sciences, 1997, 18, 468-474.	8.7	134
48	Bradykinin excites rat sympathetic neurons by inhibition of M current through a mechanism involving B2 receptors and GÎ±q/11. Neuron, 1995, 14, 399-405.	8.1	132
49	The chemokine receptor CCXâ€CKR mediates effective scavenging of CCL19 in vitro. European Journal of Immunology, 2006, 36, 1904-1916.	2.9	127
50	The insulin receptor tyrosyl kinase phosphorylates holomeric forms of the guanine nucleotide regulatory proteins Giand Go. FEBS Letters, 1987, 212, 281-288.	2.8	126
51	BRET analysis of GPCR oligomerization: newer does not mean better. Nature Methods, 2007, 4, 3-4.	19.0	126
52	Techniques: Promiscuous GÎ± proteins in basic research and drug discovery. Trends in Pharmacological Sciences, 2005, 26, 595-602.	8.7	125
53	G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today, 2006, 11, 541-549.	6.4	124
54	Agonist regulation of cellular G protein levels and distribution: mechanisms and functional implications. Trends in Pharmacological Sciences, 1993, 14, 413-418.	8.7	122

#	Article	IF	Citations
55	Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2AÂ·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function. Journal of Biological Chemistry, 2012, 287, 44301-44319.	3.4	122
56	Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. European Journal of Pharmaceutical Sciences, 2004, 21, 397-405.	4.0	119
57	Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3. Journal of Biological Chemistry, 2012, 287, 41195-41209.	3.4	116
58	Î²-Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis. Molecular Pharmacology, 2005, 67, 1229-1236.	2.3	115
59	G16 as a universal G protein adapter: implications for agonist screening strategies. Trends in Pharmacological Sciences, 1996, 17, 235-237.	8.7	114
60	The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Current Opinion in Pharmacology, 2010, 10, 23-29.	3.5	114
61	Angiotensin-(1â€“7) and angiotensin-(1â€“9): function in cardiac and vascular remodelling. Clinical Science, 2014, 126, 815-827.	4.3	114
62	Proteinâ€“protein interactions at G-protein-coupled receptors. Trends in Pharmacological Sciences, 2001, 22, 513-518.	8.7	113
63	The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities. Journal of Biological Chemistry, 2005, 280, 28663-28674.	3.4	113
64	Insights into ligand pharmacology using receptorâ€“G-protein fusion proteins. Trends in Pharmacological Sciences, 2000, 21, 24-28.	8.7	109
65	Agonist-Induced Endocytosis and Recycling of the Gonadotropin-Releasing Hormone Receptor: Effect of Î²-Arrestin on Internalization Kinetics. Molecular Endocrinology, 1998, 12, 1818-1829.	3.7	105
66	Dimers of Class A G Protein-coupled Receptors Function via Agonist-mediated Trans-activation of Associated G Proteins. Journal of Biological Chemistry, 2003, 278, 42578-42587.	3.4	101
67	Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species. Science Signaling, 2010, 3, ra20.	3.6	101
68	Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists. Journal of Biological Chemistry, 2011, 286, 10628-10640.	3.4	101
69	Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor. Journal of Biological Chemistry, 2013, 288, 17296-17312.	3.4	99
70	Antibodies against the carboxyl-terminal 5-kDa peptide of the alpha subunit of transducin crossreact with the 40-kDa but not the 39-kDa guanine nucleotide binding protein from brain.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 4095-4099.	7.1	98
71	Mechanism and Function of Drosophila capa GPCR: A Desiccation Stress-Responsive Receptor with Functional Homology to Human NeuromedinU Receptor. PLoS ONE, 2012, 7, e29897.	2.5	98
72	Conserved Polar Residues in Transmembrane Domains V, VI, and VII of Free Fatty Acid Receptor 2 and Free Fatty Acid Receptor 3 Are Required for the Binding and Function of Short Chain Fatty Acids. Journal of Biological Chemistry, 2008, 283, 32913-32924.	3.4	96

#	Article	IF	Citations
73	Multiple Interactions between Transmembrane Helices Generate the Oligomeric Î±1b-Adrenoceptor. Molecular Pharmacology, 2004, 66, 1123-1137.	2.3	95
74	The Prevalence, Maintenance, and Relevance of G Proteinâ€“Coupled Receptor Oligomerization. Molecular Pharmacology, 2013, 84, 158-169.	2.3	95
75	GPCR homo-oligomerization. Current Opinion in Cell Biology, 2019, 57, 40-47.	5.4	94
76	The Dually Acylated NH2-terminal Domain of Gi1Î± Is Sufficient to Target a Green Fluorescent Protein Reporter to Caveolin-enriched Plasma Membrane Domains. Journal of Biological Chemistry, 1999, 274, 5843-5850.	3.4	93
77	Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. British Journal of Nutrition, 2015, 113, 1677-1688.	2.3	93
78	Role of MicroRNAs 99b, 181a, and 181b in the Differentiation of Human Embryonic Stem Cells to Vascular Endothelial Cells. Stem Cells, 2012, 30, 643-654.	3.2	92
79	Treatment of intact hepatocytes with either the phorbol ester TPA or glucagon elicits the phosphorylation and functional inactivation of the inhibitory guanine nucleotide regulatory protein Gi. FEBS Letters, 1989, 243, 77-82.	2.8	91
80	Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. Kidney International, 2009, 76, 1258-1267.	5.2	91
81	Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of Î²-arrestin-2 and activate GÎ±13. Biochemical Journal, 2010, 432, 451-459.	3.7	91
82	Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. Journal of Cell Science, 2011, 124, 2349-2356.	2.0	91
83	Allosteric signaling through an mGlu2 and 5-HT _{2A} heteromeric receptor complex and its potential contribution to schizophrenia. Science Signaling, 2016, 9, ra5.	3.6	91
84	Chimaeric GÎ± proteins: their potential use in drug discovery. Trends in Pharmacological Sciences, 1999, 20, 118-124.	8.7	88
85	Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of Î²-arrestin using spot-immobilized peptide arrays. Biochemical Journal, 2007, 404, 71-80.	3.7	88
86	Staphylococcus aureusStaphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. EMBO Journal, 2012, 31, 3607-3619.	7.8	88
87	The GTP-binding regulatory proteins of neuroblastoma Ã— glioma, NG108-15, and glioma, C6, cells. FEBS Letters, 1986, 195, 225-230.	2.8	87
88	Hydrophobicity of Residue351of the G Protein Gi1Î± Determines the Extent of Activation by the Î±2A-Adrenoceptorâ€. Biochemistry, 1998, 37, 11555-11562.	2.5	87
89	Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12195-12200.	7.1	87
90	Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature, 2020, 587, 650-656.	27.8	87

#	Article	IF	Citations
91	Angiotensin1â€9 antagonises proâ€hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. Journal of Physiology, 2011, 589, 939-951.	2.9	84
92	Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse Î´ opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochemical Journal, 1996, 320, 227-235.	3.7	83
93	Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A. Journal of Biological Chemistry, 2011, 286, 37414-37428.	3.4	81
94	Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity. Journal of Medicinal Chemistry, 2016, 59, 8868-8878.	6.4	81
95	GPCR dimerisation. Life Sciences, 2003, 74, 181-188.	4.3	80
96	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Frontiers in Endocrinology, 2014, 5, 137.	3.5	80
97	The Î± Subunit of GqContributes to Muscarinic Inhibition of the M-Type Potassium Current in Sympathetic Neurons. Journal of Neuroscience, 1998, 18, 4521-4531.	3.6	79
98	Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors. Journal of Biological Chemistry, 2008, 283, 11424-11434.	3.4	78
99	Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric Modulator. Molecular Pharmacology, 2011, 80, 163-173.	2.3	78
100	Domain Swapping in the Human Histamine H₁Receptor. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 131-138.	2.5	77
101	Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS. Journal of Biological Chemistry, 2006, 281, 16757-16767.	3.4	77
102	Uncovering the Pharmacology of the G Protein-Coupled Receptor GPR40: High Apparent Constitutive Activity in Guanosine 5â€²-O-(3-[35S]thio)triphosphate Binding Studies Reflects Binding of an Endogenous Agonist. Molecular Pharmacology, 2007, 71, 994-1005.	2.3	77
103	FFA4/GPR120: Pharmacology and Therapeutic Opportunities. Trends in Pharmacological Sciences, 2017, 38, 809-821.	8.7	77
104	Interactions of the Î±2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. Biochemical Journal, 1997, 321, 721-728.	3.7	76
105	CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2â€“DOP receptor heterodimer. Biochemical Journal, 2008, 412, 245-256.	3.7	76
106	Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-Î³ production in mice. Journal of Clinical Investigation, 2007, 117, 3507-3518.	8.2	76
107	The G Protein Î± Subunit Has a Key Role in Determining the Specificity of Coupling to, but Not the Activation of, G Protein-gated Inwardly Rectifying K+ Channels. Journal of Biological Chemistry, 2000, 275, 921-929.	3.4	75
108	Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB Journal, 2012, 26, 4951-4965.	0.5	75

#	Article	IF	Citations
109	Interactions between the Mas-Related Receptors MrgD and MrgE Alter Signalling and Trafficking of MrgD. Molecular Pharmacology, 2006, 69, 479-491.	2.3	74
110	The Action and Mode of Binding of Thiazolidinedione Ligands at Free Fatty Acid Receptor 1. Journal of Biological Chemistry, 2009, 284, 17527-17539.	3.4	74
111	GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics, 2010, 26, 1804-1805.	4.1	74
112	Insulin activates glycerol-3-phosphate acyltransferase (de novo phosphatidic acid synthesis) through a phospholipid-derived mediator. Apparent involvement of Gi.alpha. and activation of a phospholipase C. Biochemistry, 1990, 29, 8735-8740.	2.5	73
113	Modulation of SF1 Neuron Activity Coordinately Regulates Both Feeding Behavior and Associated Emotional States. Cell Reports, 2017, 21, 3559-3572.	6.4	73
114	Ligand regulation of green fluorescent protein-tagged forms of the human Î²1 - and Î²2 -adrenoceptors; comparisons with the unmodified receptors. British Journal of Pharmacology, 2000, 130, 1825-1832.	5.4	72
115	High-content assays for ligand regulation of G-protein-coupled receptors. Drug Discovery Today, 2003, 8, 579-585.	6.4	72
116	The sustainability of interactions between the orexin-1 receptor and Î²-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochemical Journal, 2005, 387, 573-584.	3.7	72
117	The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. Biochemical Journal, 2013, 452, 303-312.	3.7	72
118	G-proteins and G-protein subunits mediating cholinergic inhibition of N-type calcium currents in sympathetic neurons. European Journal of Neuroscience, 1998, 10, 1654-1666.	2.6	71
119	Robustness of G Proteins in Alzheimer's Disease: An Immunoblot Study. Journal of Neurochemistry, 1991, 57, 9-14.	3.9	70
120	Visualizing differences in ligand-induced Î²-arrestin-GFP interactions and trafficking between three recently characterized Gâ€ƒprotein-coupled receptors. Journal of Neurochemistry, 2001, 77, 476-485.	3.9	70
121	G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Frontiers in Pharmacology, 2015, 6, 41.	3.5	70
122	Palmitoylation Regulates Regulators of G-protein Signaling (RGS) 16 Function. Journal of Biological Chemistry, 2003, 278, 19301-19308.	3.4	69
123	Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster Î±1B-adrenoceptor by ligands that act as inverse agonists. Biochemical Journal, 1997, 325, 733-739.	3.7	68
124	Agonist-Induced Endocytosis and Recycling of the Gonadotropin-Releasing Hormone Receptor: Effect of Â-Arrestin on Internalization Kinetics. Molecular Endocrinology, 1998, 12, 1818-1829.	3.7	68
125	A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias. Journal of Biological Chemistry, 2016, 291, 18915-18931.	3.4	66
126	High-Affinity Interactions between Human Î±1A-Adrenoceptor C-Terminal Splice Variants Produce Homo- and Heterodimers but Do Not Generate the Î±1L-Adrenoceptor. Molecular Pharmacology, 2004, 66, 228-239.	2.3	65

#	Article	IF	Citations
127	G protein-coupled receptors for free fatty acids. Cellular Signalling, 2006, 18, 1360-1365.	3.6	65
128	The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. International Immunopharmacology, 2011, 11, 1773-1779.	3.8	64
129	Agonist control of G-protein levels. Trends in Pharmacological Sciences, 1991, 12, 207-209.	8.7	63
130	Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3. Molecular Pharmacology, 2007, 71, 1349-1359.	2.3	63
131	Comparative Analysis of the Efficacy of A1Adenosine Receptor Activation of Gi/oÎ± G Proteins following Coexpression of Receptor and G Protein and Expression of A1Adenosine Receptorâ"Gi/oÎ± Fusion Proteinsâ€. Biochemistry, 1999, 38, 2272-2278.	2.5	62
132	The Regulator of G Protein Signaling RGS4 Selectively Enhances Î±2A-Adreoreceptor Stimulation of the GTPase Activity of Go1Î± and Gi2Î±. Journal of Biological Chemistry, 2000, 275, 23693-23699.	3.4	62
133	Exploring the dynamics of regulation of G protein-coupled receptors using green fluorescent protein. British Journal of Pharmacology, 1999, 128, 501-510.	5.4	61
134	Multiple Roles for the C-terminal Tail of the Chemokine Scavenger D6. Journal of Biological Chemistry, 2008, 283, 7972-7982.	3.4	61
135	Evidence for Distinct Antagonist-Revealed Functional States of 5-Hydroxytryptamine_{2A}Receptor Homodimers. Molecular Pharmacology, 2009, 75, 1380-1391.	2.3	60
136	The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120). Journal of Biological Chemistry, 2014, 289, 20345-20358.	3.4	60
137	Widespread distribution of GqÎ±/GllÎ± detected immunologically by an antipeptide antiserum directed against the predicted C-terminal decapeptide. FEBS Letters, 1991, 287, 171-174.	2.8	59
138	Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. British Journal of Pharmacology, 2009, 158, 146-153.	5.4	59
139	Agonist activation of the G proteinâ€coupled receptor GPR35 involves transmembrane domain III and is transduced via GÎ±₁₃ and Î²â€arrestinâ€2. British Journal of Pharmacology, 2011, 162, 733-748.	5.4	59
140	Agonist Occupation of an Î±2A-Adrenoreceptor-Gi1Î± Fusion Protein Results in Activation of Both Receptor-linked and Endogenous Gi Proteins. Journal of Biological Chemistry, 1998, 273, 10367-10375.	3.4	58
141	A Highly Conserved Glycine within Linker I and the Extreme C Terminus of G Protein Î± Subunits Interact Cooperatively in Switching G Protein-Coupled Receptor-to-Effector Specificity. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 78-87.	2.5	58
142	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2013, 4, 441-445.	2.8	58
143	Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands. Molecular Pharmacology, 2014, 86, 200-210.	2.3	58
144	Real Time Visualization of Agonist-mediated Redistribution and Internalization of a Green Fluorescent Protein-tagged Form of the Thyrotropin-releasing Hormone Receptor. Journal of Biological Chemistry, 1998, 273, 24000-24008.	3.4	57

#	Article	IF	Citations
145	Î²Î³ dimers derived from Goand Giproteins contribute different components of adrenergic inhibition of Ca2+channels in rat sympathetic neurones. Journal of Physiology, 1999, 518, 23-36.	2.9	57
146	G Protein Coupling and Ligand Selectivity of the D_{2L}and D₃Dopamine Receptors. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 319-330.	2.5	57
147	When simple agonism is not enough: Emerging modalities of GPCR ligands. Molecular and Cellular Endocrinology, 2011, 331, 241-247.	3.2	57
148	Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4. Journal of Biological Chemistry, 2014, 289, 18451-18465.	3.4	57
149	Using the Flp-Inâ„¢ T-Rexâ„¢ System to Regulate GPCR Expression. Methods in Molecular Biology, 2011, 746, 21-37.	0.9	56
150	Developing Chemical Genetic Approaches to Explore G Protein-Coupled Receptor Function: Validation of the Use of a Receptor Activated Solely by Synthetic Ligand (RASSL). Molecular Pharmacology, 2011, 80, 1033-1046.	2.3	56
151	Regulation of Oligomeric Organization of the Serotonin 5-Hydroxytryptamine 2C (5-HT2C) Receptor Observed by Spatial Intensity Distribution Analysis. Journal of Biological Chemistry, 2015, 290, 12844-12857.	3.4	55
152	Regional Distribution and Quantitative Measurement of the Phosphoinositidase C-Linked Guanine Nucleotide Binding Proteins G1? and Gq? in Rat Brain. Journal of Neurochemistry, 1993, 61, 845-851.	3.9	54
153	Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends in Pharmacological Sciences, 2011, 32, 317-325.	8.7	54
154	Detection of the major pertussis toxin substrate of human leukocytes with antisera raised against synthetic peptides. FEBS Letters, 1986, 209, 352-356.	2.8	53
155	Identification of Two Distinct Isoforms of the Guanine Nucleotide Binding Protein Goin Neuroblastoma Ã— Glioma Hybrid Cells: Independent Regulation During Cyclic AMP-Induced Differentiation. Journal of Neurochemistry, 1990, 55, 1890-1898.	3.9	53
156	The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35. Molecular Pharmacology, 2014, 85, 91-104.	2.3	53
157	Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Proteinâ€“Coupled Receptor 120. Molecular Pharmacology, 2016, 89, 505-520.	2.3	53
158	GTP-Binding proteins in brain and neutrophil are tethered to the plasma membrane via their amino termini. Biochemical and Biophysical Research Communications, 1987, 148, 1398-1405.	2.1	52
159	Ligand Regulation of the Quaternary Organization of Cell Surface M3 Muscarinic Acetylcholine Receptors Analyzed by Fluorescence Resonance Energy Transfer (FRET) Imaging and Homogeneous Time-resolved FRET. Journal of Biological Chemistry, 2010, 285, 23318-23330.	3.4	52
160	Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. Journal of Medicinal Chemistry, 2013, 56, 982-992.	6.4	52
161	Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Nature Chemical Biology, 2019, 15, 489-498.	8.0	52
162	Measurement of agonist-induced guanine nucleotide turnover by the G-protein Gi1Î± when constrained within an Î±2A-adrenoceptor-Gi1Î± fusion protein. Biochemical Journal, 1997, 325, 17-21.	3.7	51

#	Article	IF	Citations
163	Changes in the guanine nucleotide-binding proteins, Giand go, during differentiation of 3T3-L1 cells. FEBS Letters, 1986, 199, 103-106.	2.8	50
164	SELECTIVE DEFICIENCY OF GUANINE NUCLEOTIDE-BINDING PROTEIN Go IN TWO DOPAMINE-RESISTANT PITUITARY TUMORS. Endocrinology, 1988, 122, 1176-1178.	2.8	50
165	Selective Interactions between Helix VIII of the Human Î¼-Opioid Receptors and the C Terminus of Periplakin Disrupt G Protein Activation. Journal of Biological Chemistry, 2003, 278, 33400-33407.	3.4	50
166	Identification of a Novel Site within G Protein Î± Subunits Important for Specificity of Receptor-G Protein Interaction. Molecular Pharmacology, 2004, 66, 250-259.	2.3	50
167	Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties. Journal of Medicinal Chemistry, 2012, 55, 6624-6628.	6.4	50
168	Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. Scientific Reports, 2017, 7, 17953.	3.3	50
169	Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. Journal of Biological Chemistry, 2016, 291, 303-317.	3.4	49
170	Rescue of Functional Interactions between the Î±2A-Adrenoreceptor and Acylation-resistant Forms of Gi1Î± by Expressing the Proteins from Chimeric Open Reading Frames. Journal of Biological Chemistry, 1997, 272, 24673-24678.	3.4	48
171	Tissue-specific regulation of GTP-binding protein and muscarinic acetylcholine receptor levels during cardiac development. Biochemistry, 1987, 26, 4876-4884.	2.5	47
172	Morphine Desensitization, Internalization, and Down-Regulation of the Î¼ Opioid Receptor Is Facilitated by Serotonin 5-Hydroxytryptamine_{2A} Receptor Coactivation. Molecular Pharmacology, 2008, 74, 1278-1291.	2.3	47
173	Experimental Challenges to Targeting Poorly Characterized GPCRs: Uncovering the Therapeutic Potential for Free Fatty Acid Receptors. Advances in Pharmacology, 2011, 62, 175-218.	2.0	47
174	A general method to quantify ligand-driven oligomerization from fluorescence-based images. Nature Methods, 2019, 16, 493-496.	19.0	47
175	Kinetics of Ternary Complex Formation with Fusion Proteins Composed of the A1-Adenosine Receptor and G Protein Î±-Subunits. Journal of Biological Chemistry, 1999, 274, 30571-30579.	3.4	46
176	Palmitoylation Regulates Regulator of G-protein Signaling (RGS) 16 Function. Journal of Biological Chemistry, 2003, 278, 19309-19316.	3.4	46
177	Analysis of inverse agonism at the Î´ opioid receptor after expression in Rat 1 fibroblasts. Biochemical Journal, 1996, 315, 227-234.	3.7	45
178	Coordinated Agonist Regulation of Receptor and G Protein Palmitoylation and Functional Rescue of Palmitoylation-deficient Mutants of the G Protein G11Î± following Fusion to the Î±1b-Adrenoreceptor. Journal of Biological Chemistry, 2001, 276, 35883-35890.	3.4	45
179	Human D2 and D4 dopamine receptors couple through Î²Î³ G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology, 1998, 37, 983-987.	4.1	44
180	Distribution and relative levels of expression of the phosphoinositidase-C-linked G-proteins GqÎ± and G11Î±: Absence of G11Î± in human platelets and haemopoietically derived cell lines. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1179, 208-212.	4.1	43

#	Article	IF	Citations
181	Regulation of Spontaneous Activity of the Î´â€Opioid Receptor: Studies of Inverse Agonism in Intact Cells. Journal of Neurochemistry, 1997, 69, 2115-2122.	3.9	43
182	GTP analogues cause release of the alpha subunit of the GTP binding protein, GO, from the plasma membrane of NG108-15 cells. Biochemical and Biophysical Research Communications, 1988, 152, 243-251.	2.1	42
183	Multiple defects occur in the guanine nucleotide regulatory protein system in liver plasma membranes of obese (fa/fa) but not lean (Fa/Fa) zucker rats: Loss of functional G1 and abnormal Gs function. Cellular Signalling, 1989, 1, 9-22.	3.6	42
184	Agonist-induced Internalization of the G Protein G11Î± and Thyrotropin-releasing Hormone Receptors Proceed on Different Time Scales. Journal of Biological Chemistry, 1998, 273, 21699-21707.	3.4	42
185	Agonists activate Gi1Î± or Gi2Î± fused to the human mu opioid receptor differently. Journal of Neurochemistry, 2002, 81, 1372-1382.	3.9	42
186	Src-mediated RGS16 Tyrosine Phosphorylation Promotes RGS16 Stability. Journal of Biological Chemistry, 2003, 278, 16107-16116.	3.4	42
187	Î²-Arrestin-Dependent Spontaneous Î±1a-Adrenoceptor Endocytosis Causes Intracellular Transportation of Î±-Blockers via Recycling Compartments. Molecular Pharmacology, 2005, 67, 992-1004.	2.3	42
188	Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics, 2007, 8, 177.	2.6	42
189	Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35. ACS Pharmacology and Translational Science, 2020, 3, 801-812.	4.9	42
190	Altered G-protein expression and adenylate cyclase activity in platelets of non-insulin-dependent diabetic (NIDDM) male subjects. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1991, 1096, 127-133.	3.8	41
191	Wortmannin-sensitive Activation of p70 by Endogenous and Heterologously Expressed G -coupled Receptors. Journal of Biological Chemistry, 1996, 271, 8537-8540.	3.4	41
192	Selective interactions of Î¼-opioid receptors with pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the c-terminal tail in coupling. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1359, 263-274.	4.1	41
193	Visualization of Agonist-induced Association and Trafficking of Green Fluorescent Protein-tagged Forms of Both Î²-Arrestin-1 and the Thyrotropin-releasing Hormone Receptor-1. Journal of Biological Chemistry, 1999, 274, 23263-23269.	3.4	41
194	Functional Homomers and Heteromers of Dopamine D2L and D3 Receptors Co-exist at the Cell Surface. Journal of Biological Chemistry, 2012, 287, 8864-8878.	3.4	41
195	The human muscarinic M1 acetylcholine receptor, when expressed in CHO cells, activates and downregulates both GqÎ± and G11Î± equally and non-selectively. FEBS Letters, 1993, 324, 241-245.	2.8	40
196	Agonist regulation of adenylate cyclase activity in neuroblastoma Ã— glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the Î²2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. Biochemical Journal, 1996, 318, 1033-1039.	3.7	40
197	Functional Complementation and the Analysis of Opioid Receptor Homodimerization. Molecular Pharmacology, 2005, 68, 905-915.	2.3	40
198	Mutations of Î²-arrestin 2 that limit self-association also interfere with interactions with the Î²2-adrenoceptor and the ERK1/2 MAPKs: implications for Î²2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochemical Journal, 2008, 413, 51-60.	3.7	40

#	Article	IF	Citations
199	Antagonists of GPR35 Display High Species Ortholog Selectivity and Varying Modes of Action. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 683-695.	2.5	40
200	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer. Journal of Medicinal Chemistry, 2016, 59, 4849-4858.	6.4	40
201	The human Î´ opioid receptor activates Gi1Î± more efficiently than Go1Î±. Journal of Neurochemistry, 2001, 76, 1805-1813.	3.9	39
202	G proteinâ€“coupled receptor modulation with pepducins: moving closer to the clinic. Annals of the New York Academy of Sciences, 2011, 1226, 34-49.	3.8	39
203	The Dynamics of Formation and Action of the Ternary Complex Revealed in Living Cells Using a G-protein-gated K+ Channel as a Biosensor. Journal of Biological Chemistry, 2003, 278, 10851-10858.	3.4	38
204	Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric Î²2-adrenoceptor. Cellular Signalling, 2007, 19, 1928-1938.	3.6	38
205	Novel Role for Proteinase-activated Receptor 2 (PAR2) in Membrane Trafficking of Proteinase-activated Receptor 4 (PAR4). Journal of Biological Chemistry, 2012, 287, 16656-16669.	3.4	38
206	Immunochemical and electrophoretic characterization of the major pertussis toxin substrate of the RAW264 macrophage cell line. Biochemistry, 1988, 27, 2040-2046.	2.5	37
207	Melatonin Receptors Couple Through a Cholera Toxin-Sensitive Mechanism to Inhibit Cyclic AMP in the Ovine Pituitary. Journal of Neuroendocrinology, 1995, 7, 361-369.	2.6	37
208	The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Cellular Signalling, 1996, 8, 87-95.	3.6	37
209	Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs. Journal of Biological Chemistry, 2016, 291, 13132-13146.	3.4	37
210	The emerging pharmacology and function of GPR35 in the nervous system. Neuropharmacology, 2017, 113, 661-671.	4.1	37
211	Analysis of the C-Terminal Tail of the Rat Thyrotropin-Releasing Hormone Receptor-1 in Interactions and Cointernalization with Î²-Arrestin 1-Green Fluorescent Protein. Molecular Pharmacology, 2001, 59, 375-385.	2.3	37
212	Degradation of G11Î±/GqÎ± Is Accelerated by Agonist Occupancy of Î±1A/D, Î±1B, and Î±1C Adrenergic Receptors. Journal of Biological Chemistry, 1995, 270, 17196-17203.	3.4	36
213	Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant Î²2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins. Molecular Pharmacology, 1999, 56, 1182-1191.	2.3	36
214	Visualization of distinct patterns of subcellular redistribution of the thyrotropin-releasing hormone receptor-1 and GqÎ± /G11Î± induced by agonist stimulation. Biochemical Journal, 1999, 340, 529-538.	3.7	36
215	Opioid Receptors and Their Interacting Proteins. NeuroMolecular Medicine, 2005, 7, 051-060.	3.4	36
216	Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective Î±1b-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. Biochemical Journal, 2009, 417, 161-172.	3.7	36

#	Article	IF	Citations
217	The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction. Current Drug Targets, 2012, 13, 80-102.	2.1	36
218	Alterations in the activity of adenylate cyclase and high affinity GTPase in Alzheimer's disease. Brain Research, 1993, 622, 35-42.	2.2	35
219	Agonist-induced Transfer of the alpha Subunits of the Guanine-nucleotide-binding Regulatory Proteins Gq and G11, and of Muscarinic m1 Acetylcholine Receptors from Plasma Membranes to a Light-vesicular Membrane Fraction. FEBS Journal, 1994, 224, 455-462.	0.2	35
220	Up-regulation of a constitutively active form of theÎ²2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Letters, 1996, 399, 108-112.	2.8	35
221	Periplakin Interferes with G Protein Activation by the Melanin-concentrating Hormone Receptor-1 by Binding to the Proximal Segment of the Receptor C-terminal Tail. Journal of Biological Chemistry, 2005, 280, 8208-8220.	3.4	35
222	Growth Hormone Secretagogues and Growth Hormone Releasing Peptides Act As Orthosteric Super-Agonists but Not Allosteric Regulators for Activation of the G Protein GÎ±_{o1}by the Ghrelin Receptor. Molecular Pharmacology, 2009, 76, 802-811.	2.3	35
223	High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochemical Journal, 2010, 432, 21-35.	3.7	35
224	G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. British Journal of Nutrition, 2014, 111, S3-S7.	2.3	35
225	Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35. Journal of Immunology, 2018, 201, 714-724.	0.8	35
226	Mitogenic signalling by Î´ opioid receptors expressed in Rat-1 fibroblasts involves activation of the p70s6k/p85s6k S6 kinase. Biochemical Journal, 1997, 325, 217-222.	3.7	34
227	Measurement of agonist efficacy using an Î±2A-adrenoceptor-Gi1Î± fusion protein. FEBS Letters, 1997, 419, 141-146.	2.8	34
228	Modulation of Relative Intrinsic Activity of Agonists at theAlpha-2A Adrenoceptor by Mutation of Residue 351 of G Protein Gi1Î±. Molecular Pharmacology, 1999, 55, 195-201.	2.3	34
229	Lymphocyte trafficking through the bloodâ€“brain barrier is dependent on endothelial cell heterotrimeric Gâ€protein signaling. FASEB Journal, 2002, 16, 1185-1194.	0.5	34
230	Ligandâ€induced internalization of the orexin OX₁ and cannabinoid CB₁ receptors assessed via Nâ€terminal SNAP and CLIPâ€tagging. British Journal of Pharmacology, 2011, 162, 1439-1452.	5.4	34
231	Dietary fibers inhibit obesity in mice, but host responses in the cecum and liver appear unrelated to fiber-specific changes in cecal bacterial taxonomic composition. Scientific Reports, 2018, 8, 15566.	3.3	34
232	CypHer 5: A Generic Approach for Measuring the Activation and Trafficking of G Protein-Coupled Receptors in Live Cells. Assay and Drug Development Technologies, 2003, 1, 251-259.	1.2	33
233	Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. Analytical and Bioanalytical Chemistry, 2010, 398, 167-180.	3.7	33
234	Eukaryotic Translation Initiation Factor 3, Subunit a, Regulates the Extracellular Signal-Regulated Kinase Pathway. Molecular and Cellular Biology, 2012, 32, 88-95.	2.3	33

#	Article	IF	Citations
235	Indomethacin Treatment Prevents High Fat Diet-induced Obesity and Insulin Resistance but Not Glucose Intolerance in C57BL/6J Mice. Journal of Biological Chemistry, 2014, 289, 16032-16045.	3.4	33
236	Metabolic and inflammatory functions of short-chain fatty acid receptors. Current Opinion in Endocrine and Metabolic Research, 2021, 16, 1-9.	1.4	33
237	Effective Information Transfer from the Î±1b-Adrenoceptor to GÎ±11 Requires Both Î²/Î³ Interactions and an Aromatic Group Four Amino Acids from the C Terminus of the G Protein. Journal of Biological Chemistry, 2002, 277, 25707-25714.	3.4	32
238	Lentivirus-mediated Reprogramming of Somatic Cells in the Absence of Transgenic Transcription Factors. Molecular Therapy, 2010, 18, 2139-2145.	8.2	32
239	High-Throughput Identification and Characterization of Novel, Species-selective GPR35 Agonists. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 568-578.	2.5	32
240	Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43). Journal of Medicinal Chemistry, 2017, 60, 5638-5645.	6.4	32
241	Guanine nucleotide regulation of the pertussis and cholera toxin substrates of rat glioma C6 BU1 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1987, 929, 197-202.	4.1	31
242	Guanine nucleotide regulatory protein levels and function in spontaneously hypertensive rat vascular smooth-muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1136, 290-296.	4.1	31
243	Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. Biochemical Journal, 1999, 342, 457-463.	3.7	31
244	The orexin OX1 receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands. Biochemical Journal, 2011, 439, 171-183.	3.7	31
245	Spatial intensity distribution analysis quantifies the extent and regulation of homodimerization of the secretin receptor. Biochemical Journal, 2017, 474, 1879-1895.	3.7	31
246	Resolution of Inverse Agonist-Induced Up-Regulation from Constitutive Activity of Mutants of the Î±1b-Adrenoceptor. Molecular Pharmacology, 2000, 58, 438-448.	2.3	30
247	Multiple pertussis toxin-sensitive G-proteins can couple receptors to GIRK channels in rat sympathetic neurons when expressed heterologously, but only native Gi-proteins do soin situ. European Journal of Neuroscience, 2001, 14, 283-292.	2.6	30
248	The Specificity and Molecular Basis of Î±₁-Adrenoceptor and CXCR Chemokine Receptor Dimerization. Journal of Molecular Neuroscience, 2005, 26, 161-168.	2.3	30
249	Interaction of Neurochondrin with the Melanin-concentrating Hormone Receptor 1 Interferes with G Protein-coupled Signal Transduction but Not Agonist-mediated Internalization. Journal of Biological Chemistry, 2006, 281, 32496-32507.	3.4	30
250	Roundabout 1 exists predominantly as a basal dimeric complex and this is unaffected by binding of the ligand Slit2. Biochemical Journal, 2014, 461, 61-73.	3.7	30
251	A Molecular Mechanism for Sequential Activation of a G Protein-Coupled Receptor. Cell Chemical Biology, 2016, 23, 392-403.	5.2	30
252	Genome Editing Provides New Insights into Receptor-Controlled Signalling Pathways. Trends in Pharmacological Sciences, 2018, 39, 481-493.	8.7	30

#	Article	IF	Citations
253	Context-Dependent Signaling of CXC Chemokine Receptor 4 and Atypical Chemokine Receptor 3. Molecular Pharmacology, 2019, 96, 778-793.	2.3	30
254	Identification of both Gi 2 and a novel, immunologically distinct, form of Go in rat myometrial membranes. FEBS Letters, 1989, 244, 411-416.	2.8	29
255	Differential capacities of the RGS1, RGS16 and RGS-GAIP regulators of G protein signaling to enhance Î±2A-adrenoreceptor agonist-stimulated GTPase activity of Go1Î±. Journal of Neurochemistry, 2001, 78, 797-806.	3.9	29
256	Measurement of Agonist-Dependent and -Independent Signal Initiation of Î±1b-Adrenoceptor Mutants by Direct Analysis of Guanine Nucleotide Exchange on the G Protein GÎ±11. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1080-1088.	2.5	29
257	Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 3-14.	2.6	29
258	Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4. Molecular Pharmacology, 2017, 91, 630-641.	2.3	29
259	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2018, 61, 9534-9550.	6.4	29
260	Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial. Journal of Medicinal Chemistry, 2020, 63, 13526-13545.	6.4	29
261	Minireview: The Effects of Species Ortholog and SNP Variation on Receptors for Free Fatty Acids. Molecular Endocrinology, 2013, 27, 1177-1187.	3.7	28
262	G-proteins in experimental hypertension: a study of spontaneously hypertensive rat myocardial and renal cortical plasma membranes. Journal of Hypertension, 1993, 11, 365-372.	0.5	27
263	Quantitative stoichiometry of the proteins of the stimulatory arm of the adenylyl cyclase cascade in neuroblastoma x glioma hybrid, NG108-15 cells. FEBS Journal, 1994, 219, 135-143.	0.2	27
264	Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). Handbook of Experimental Pharmacology, 2016, 236, 17-32.	1.8	27
265	Fatty acid 16:4(nâ€3) stimulates a GPR120â€induced signaling cascade in splenic macrophages to promote chemotherapy resistance.. FASEB Journal, 2017, 31, 2195-2209.	0.5	27
266	Therapeutic validation of an orphan G proteinâ€coupled receptor: The case of GPR84. British Journal of Pharmacology, 2022, 179, 3529-3541.	5.4	27
267	The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs. Current Topics in Medicinal Chemistry, 2013, 13, 14-25.	2.1	26
268	The Î±2B adrenergic receptor of undifferentiated neuroblastoma Ã— glioma hybrid NG108-15 cells, interacts directly with the guanine nucleotide binding protein, Gi2. FEBS Letters, 1990, 269, 430-434.	2.8	25
269	Enhanced Detection of Receptor Constitutive Activity in the Presence of Regulators of G Protein Signaling: Applications to the Detection and Analysis of Inverse Agonists and Low-Efficacy Partial Agonists. Molecular Pharmacology, 2002, 61, 1211-1221.	2.3	25
270	Elevated levels of the guanine nucleotide binding protein, Go , are associated with differentiation of neuroblastoma Ã— glioma hybrid cells. FEBS Letters, 1989, 244, 113-118.	2.8	24

#	Article	IF	Citations
271	S 14506: novel receptor coupling at 5-HT1A receptors. Neuropharmacology, 2001, 40, 334-344.	4.1	24
272	Spatial Intensity Distribution Analysis: Studies of G Protein-Coupled Receptor Oligomerisation. Trends in Pharmacological Sciences, 2018, 39, 175-186.	8.7	24
273	The Orphan Receptor GPR35 Contributes to Angiotensin IIâ€“Induced Hypertension and Cardiac Dysfunction in Mice. American Journal of Hypertension, 2018, 31, 1049-1058.	2.0	24
274	A Cysteine-3 to Serine Mutation of the G-Protein Gi1Î± Abrogates Functional Activation by the Î±2A-Adrenoceptor but Not Interactions with the Î²Î³ Complex. Biochemistry, 1997, 36, 10620-10629.	2.5	23
275	Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. Biochemical Journal, 2000, 346, 711-718.	3.7	23
276	Î¼-Î´ Opioid Receptor Functional Interaction: Insight Using Receptor-G Protein Fusions. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 683-690.	2.5	23
277	Novel pharmacological applications of G-protein-coupled receptorâ€“G protein fusions. Current Opinion in Pharmacology, 2007, 7, 521-526.	3.5	23
278	G-Protein-Coupled Receptor 35 Mediates Human Saphenous Vein Vascular Smooth Muscle Cell Migration and Endothelial Cell Proliferation. Journal of Vascular Research, 2015, 52, 383-395.	1.4	23
279	Analysis of Human Dopamine D3 Receptor Quaternary Structure. Journal of Biological Chemistry, 2015, 290, 15146-15162.	3.4	23
280	Receptor selectivity between the G proteins GÎ± ₁₂ and GÎ± ₁₃ is defined by a single leucineâ€toâ€isoleucine variation. FASEB Journal, 2019, 33, 5005-5017.	0.5	23
281	Differential distribution of signal-transducing G-proteins in retina. Brain Research, 1987, 423, 237-246.	2.2	22
282	Immunological identification of the Î± subunit of G13, a novel guanine nucleotide binding protein. FEBS Letters, 1992, 297, 186-188.	2.8	22
283	Signal Sorting by G-Protein-Linked Receptors. Advances in Pharmacology, 1995, 32, 1-29.	2.0	22
284	New Aspects of G-Protein-Coupled Receptor Signalling and Regulation. Trends in Endocrinology and Metabolism, 1998, 9, 13-19.	7.1	22
285	G proteinâ€coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35. British Journal of Pharmacology, 2018, 175, 2543-2553.	5.4	22
286	Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. Journal of Biological Chemistry, 2022, 298, 101655.	3.4	22
287	Efficacy of inverse agonists in cells overexpressing a constitutively active Î² 2 -adrenoceptor and type II adenylyl cyclase. British Journal of Pharmacology, 1998, 123, 335-343.	5.4	21
288	Selective Activation of a Chimeric Gi1/GsG Protein Î± Subunit by the Human IP Prostanoid Receptor: Analysis Using Agonist Stimulation of High Affinity GTPase Activity and [35S]Guanosine-5â€²-O-(3-thio)triphosphate Binding. Molecular Pharmacology, 1998, 54, 249-257.	2.3	21

#	Article	IF	Citations
289	Thyrotropin-releasing hormone-induced depletion of Gq Î±/G11 Î± proteins from detergent-insensitive membrane domains. FEBS Letters, 1999, 464, 35-40.	2.8	21
290	Action of Pasteurella multocida toxin on GÎ±q is persistent and independent of interaction with G-protein-coupled receptors. Cellular Signalling, 2007, 19, 2174-2182.	3.6	21
291	Intramolecular Fluorescence Resonance Energy Transfer (FRET) Sensors of the Orexin OX1 and OX2 Receptors Identify Slow Kinetics of Agonist Activation. Journal of Biological Chemistry, 2012, 287, 14937-14949.	3.4	21
292	A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias. Scientific Reports, 2017, 7, 13741.	3.3	21
293	Chemogenetics defines a short-chain fatty acid receptor gutâ€“brain axis. ELife, 2022, 11, .	6.0	21
294	G-proteins in essential hypertension: a study of human platelet plasma membranes. Journal of Hypertension, 1993, 11, 543-550.	0.5	20
295	Interaction of the G-protein G11Î± with receptors and phosphoinositidase C:. FEBS Letters, 1997, 407, 257-260.	2.8	20
296	Generation and Analysis of Constitutively Active and Physically Destabilized Mutants of the Human Î²1-Adrenoceptor. Molecular Pharmacology, 2002, 62, 747-755.	2.3	20
297	A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor. BMC Biochemistry, 2004, 5, 12.	4.4	20
298	Analysis of endogenous S1P and LPA receptor expression in CHO-K1 cells. Gene, 2005, 350, 59-63.	2.2	20
299	Carvedilol-induced antagonism of angiotensin II: a matter of Î±1-adrenoceptor blockade. Journal of Hypertension, 2006, 24, 1355-1363.	0.5	20
300	Antibodies that identify only the active conformation of G_ifamily G protein Î± subunits. FASEB Journal, 2008, 22, 1924-1932.	0.5	20
301	GPCR Oligomerization and Receptor Trafficking. Methods in Enzymology, 2013, 521, 69-90.	1.0	20
302	The Molecular Basis of Oligomeric Organization of the Human M₃ Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2015, 87, 936-953.	2.3	20
303	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 2841-2846.	6.4	20
304	On-target and off-target effects of novel orthosteric and allosteric activators of GPR84. Scientific Reports, 2019, 9, 1861.	3.3	20
305	Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. Science Translational Medicine, 2020, 12, .	12.4	20
306	G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis. Communications Biology, 2021, 4, 585.	4.4	20

#	Article	IF	Citations
307	Biphasic regulation of adenylate cyclase by cholera toxin in neuroblastoma Ã— glioma hybrid cells is due to the activation and subsequent loss of the Î± subunit of the stimulatory GTP binding proteins (Gs). Cellular Signalling, 1990, 2, 139-151.	3.6	19
308	Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor. British Journal of Pharmacology, 2001, 133, 315-323.	5.4	19
309	Î'â€Opioid receptors exhibit high efficiency when activating trimeric G proteins in membrane domains. Journal of Neurochemistry, 2003, 85, 34-49.	3.9	19
310	Selectivity and functional consequences of interactions of family A G proteinâ€coupled receptors with neurochondrin and periplakin. Journal of Neurochemistry, 2009, 109, 182-192.	3.9	19
311	The use of specific antibodies to identify and quantify guanine nucleotide-binding proteins. Biochemical Society Transactions, 1987, 15, 42-45.	3.4	18
312	A Key Serine for the GTPase-Activating Protein Function of Regulator of G Protein Signaling Proteins Is Not a General Target for 14-3-3 Interactions. Molecular Pharmacology, 2005, 68, 1821-1830.	2.3	18
313	Expression of gsÎ±, connexin-43, connexin-26, and EP1, 3, and 4 receptors in myometrium of prelabor singleton versus multiple gestations and the effects of mechanical stretch and steroids on gsÎ±. Journal of the Society for Gynecologic Investigation, 2002, 9, 299-307.	1.7	18
314	Selective phosphorylation of threonine residues defines GPR84â€"arrestin interactions of biased ligands. Journal of Biological Chemistry, 2022, 298, 101932.	3.4	18
315	Chronic exposure of rat glioma C6 cells to cholera toxin induces loss of the Î±-subunit of the stimulatory guanine nucleotide-binding protein (Gs). European Journal of Pharmacology, 1990, 188, 203-209.	2.6	17
316	Involvement of G-protein Î±il subunits in activation of G-protein gated inward rectifying K+ channels (GIRK1) by human NPY1 receptors. British Journal of Pharmacology, 1995, 116, 2346-2348.	5.4	17
317	Functional analysis of a human A1adenosine receptor/green fluorescent protein/Gi1Î± fusion protein following stable expression in CHO cells. FEBS Letters, 1999, 462, 61-65.	2.8	17
318	Dominant Portion of Thyrotropin-Releasing Hormone Receptor Is Excluded from Lipid Domains. Detergent-Resistant and Detergent-Sensitive Pools of TRH Receptor and GqÎ±/G11Î± Protein. Journal of Biochemistry, 2005, 138, 111-125.	1.7	17
319	Regulation of cardiovascular remodeling by the counter-regulatory axis of the reninâ€"angiotensin system. Future Cardiology, 2013, 9, 23-38.	1.2	17
320	A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization. Scientific Reports, 2017, 7, 2134.	3.3	17
321	Ligand Rescue of Constitutively Active Mutant Receptors. NeuroSignals, 2002, 11, 29-33.	0.9	16
322	Expression of the Human Î²2-Adrenoceptor in NCB20 Cells Results in Agonist Activation of Adenylyl Cyclase and Agonist-Mediated Selective Down-Regulation of GsÎ±. Journal of Neurochemistry, 2002, 65, 545-553.	3.9	16
323	Mechanism of Action of Gqto Inhibit GÎ²Î³ Modulation of CaV2.2 Calcium Channels: Probed by the Use of Receptor-GÎ± Tandems. Molecular Pharmacology, 2003, 63, 832-843.	2.3	16
324	Succinct synthesis of saturated hydroxy fatty acids andin vitroevaluation of all hydroxylauric acids on FFA1, FFA4 and GPR84. MedChemComm, 2017, 8, 1360-1365.	3.4	16

#	Article	IF	Citations
325	Guanine nucleotide regulatory proteins in insulin's action and in diabetes. Biochemical Society Transactions, 1989, 17, 627-629.	3.4	15
326	Concerted stimulation and deactivation of pertussis toxin-sensitive Gâ€ƒproteins by chimeric Gâ€ƒprotein-coupled receptor-regulator of Gâ€ƒprotein signaling 4 fusion proteins: analysis of the contribution of palmitoylated cysteine residues to the GAP activity o. Journal of Neurochemistry, 2003, 85, 1289-1298.	3.9	15
327	Activation of an Î±2A-adrenoceptorâ€“Gî±o1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor. Biochemical Journal, 2005, 385, 197-206.	3.7	15
328	MicroRNA regulation of endothelial homeostasis and commitmentâ€”implications for vascular regeneration strategies using stem cell therapies. Free Radical Biology and Medicine, 2013, 64, 52-60.	2.9	15
329	Muscarinic receptor oligomerization. Neuropharmacology, 2018, 136, 401-410.	4.1	15
330	Design, Synthesis, and Evaluation of a Diazirine Photoaffinity Probe for Ligand-Based Receptor Capture Targeting G Proteinâ€“Coupled Receptors. Molecular Pharmacology, 2019, 95, 196-209.	2.3	15
331	Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t. Journal of Biological Chemistry, 2021, 296, 100139.	3.4	15
332	Differences in the Signaling Pathways of Î±1A- and Î±1B-Adrenoceptors Are Related to Different Endosomal Targeting. PLoS ONE, 2013, 8, e64996.	2.5	15
333	Tissue distribution and subcellular location of guanine nucleotide binding proteins: â€” Implications for cellular signalling. Cellular Signalling, 1989, 1, 411-419.	3.6	14
334	A constitutively active mutant of the Î±1B-adrenergic receptor can cause greater agonist-dependent down-regulation of the G-proteins GqÎ± and G11Î± than the wild-type receptor. Biochemical Journal, 1996, 320, 79-86.	3.7	14
335	Loss of activation of Gsbut not Gifollowing expression of an Î±2A-adrenoceptor-Gi1Î± fusion protein. FEBS Letters, 1998, 436, 46-50.	2.8	14
336	Construction and analysis of function of G protein-coupled receptor-G protein fusion proteins. Methods in Enzymology, 2002, 343, 260-273.	1.0	14
337	Long-term agonist stimulation of IP prostanoid receptor depletes the cognate GsÎ± protein in membrane domains but does not change the receptor level. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1691, 51-65.	4.1	14
338	Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 2010, 38, 1058-1061.	3.4	14
339	MicroRNAs regulating cell pluripotency and vascular differentiation. Vascular Pharmacology, 2011, 55, 69-78.	2.1	14
340	Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. Biochemical Journal, 1999, 342, 457.	3.7	14
341	Stimulus-response coupling in FMLP-stimulated U937 monocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1990, 1051, 71-77.	4.1	13
342	Agonist regulation of cellular levels of the stimulatory guanine nucleotide-binding protein, Gs, in wild type and transfected neuroblastoma-glioma hybrid NG108-15 cells. Biochemical Society Transactions, 1993, 21, 432-435.	3.4	13

#	Article	IF	Citations
343	Equivalent regulation of wild type and an epitope-tagged variant of GsÎ± by the IP prostanoid receptor following expression in neuroblastoma Ã— glioma hybrid, NG108-15, cells. FEBS Letters, 1994, 353, 231-234.	2.8	13
344	An Asp79Asn mutation of the Î±2A-adrenoceptor interferes equally with agonist activation of individual GiÎ±-family G protein subtypes. FEBS Letters, 1999, 462, 459-463.	2.8	13
345	Ligand Specific Up-Regulation of a Renilla reniformis Luciferase-Tagged, Structurally Unstable Muscarinic M3 Chimeric G Protein-Coupled Receptor. Molecular Pharmacology, 2003, 64, 1474-1484.	2.3	13
346	Autoimmune Disease-Associated Histamine Receptor H1 Alleles Exhibit Differential Protein Trafficking and Cell Surface Expression. Journal of Immunology, 2008, 180, 7471-7479.	0.8	13
347	Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment. Stem Cell Research and Therapy, 2013, 4, 36.	5.5	13
348	Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors. Cellular Signalling, 2017, 36, 98-107.	3.6	13
349	The Use of Receptor G-Protein Fusion Proteins for the Study of Ligand Activity. Receptors and Channels, 2002, 8, 309-317.	1.1	13
350	Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
351	The use of anti-peptide antisera to probe interactions between receptors and guanine nucleotide binding proteins. Biochemical Society Transactions, 1988, 16, 434-437.	3.4	12
352	[21] Specificity and functional applications of antipeptide antisera which identify G-protein Î± subunits. Methods in Enzymology, 1994, 237, 268-283.	1.0	12
353	Cold-induced reduction in GiÎ± proteins in brown adipose tissue. Effects on the cellular hypersensitization to noradrenaline caused by pertussis-toxin treatment. Biochemical Journal, 1996, 314, 761-768.	3.7	12
354	Agonist-Mediated Tyrosine Phosphorylation of Isoforms of the Shc Adapter Protein by the Î´ Opioid Receptor. Cellular Signalling, 1997, 9, 423-429.	3.6	12
355	Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening. Expert Opinion on Drug Discovery, 2010, 5, 461-474.	5.0	12
356	Binding to GDP-agarose identifies a novel 60kDa substrate for the insulin receptor tyrosyl kinase in mouse NIH-3T3 cells expressing high concentrations of the human insulin receptor. Biochemical and Biophysical Research Communications, 1989, 158, 743-748.	2.1	11
357	Guanine nucleotide binding proteins in neuroblastoma Ã— glioma hybrid, NG108-15, cells. regulation of expression and function. International Journal of Biochemistry & Cell Biology, 1990, 22, 701-707.	0.5	11
358	Overexpression of GsÎ± in NG108-15, neuroblastoma X glioma cells: effects on receptor regulation of the stimulatory adenylyl cyclase cascade. FEBS Letters, 1996, 397, 325-330.	2.8	11
359	Quantitative analysis of a cysteine351glycine mutation in the G protein Gi1Î±: effect on Î±2A-adrenoceptor-Gi1Î± fusion protein activation. FEBS Letters, 1998, 428, 17-22.	2.8	11
360	Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84. ACS Pharmacology and Translational Science, 2021, 4, 1598-1613.	4.9	11

#	Article	IF	Citations
361	Opioid Regulation of Mu Receptor Internalisation: Relevance to the Development of Tolerance and Dependence. CNS and Neurological Disorders - Drug Targets, 2010, 9, 616-626.	1.4	11
362	Foetal calf serum enhances cholera toxin-catalysed ADP-ribosylation of the pertussis toxin-sensitive guanine nucleotide binding protein, Gi2, in rat glioma C6BU1 cells. Cellular Signalling, 1989, 1, 65-74.	3.6	10
363	Prostanoid-mediated downregulation of Gs in NG108â€“15 cells. Biochemical Society Transactions, 1991, 19, 81S-81S.	3.4	10
364	Guanine nucleotide regulatory protein alterations in young Milan hypertensive strain rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1994, 1225, 149-157.	3.8	10
365	Use of [3H]Triphenylmethylphosphomum Cation for Estimating Membrane Potential in Neuroblastoma Cells. Journal of Neurochemistry, 1984, 43, 1515-1521.	3.9	9
366	Is Promiscuity of G Protein Interaction an Issue in the Classification of Receptors?. Annals of the New York Academy of Sciences, 1997, 812, 126-132.	3.8	9
367	Visualization of distinct patterns of subcellular redistribution of the thyrotropin-releasing hormone receptor-1 and GqÎ± /G11Î± induced by agonist stimulation. Biochemical Journal, 1999, 340, 529.	3.7	9
368	Oligomeric structure of the Î±1b-adrenoceptor: Comparisons with rhodopsin. Vision Research, 2006, 46, 4434-4441.	1.4	9
369	Functional interactions between the Î±1b-adrenoceptor and GÎ±11 are compromised by de-palmitoylation of the G protein but not of the receptor. Cellular Signalling, 2006, 18, 1244-1251.	3.6	9
370	Role of metabotropic glutamate receptors in CNS disorders. , 2010, , 321-379.		9
371	Novel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor. CKJ: Clinical Kidney Journal, 2011, 4, 158-163.	2.9	9
372	Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers. Journal of Biological Chemistry, 2015, 290, 14785-14796.	3.4	9
373	Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. ACS Pharmacology and Translational Science, 2018, 1, 119-133.	4.9	9
374	Biochemical estimation of membrane potential in neuroblastoma cells. Biochemical Society Transactions, 1981, 9, 414-415.	3.4	8
375	Apparent down-regulation of muscarinic acetylcholine receptors of neuroblastoma cells by pilocarpine is due to occluded agonist. European Journal of Pharmacology, 1983, 91, 223-228.	3.5	8
376	Multiple heterotrimeric guanine nucleotide binding proteins: roles in the determination of cellular signalling specificity. Biochemical Society Transactions, 1992, 20, 135-140.	3.4	8
377	Reciprocal mutations of highly conserved residues in transmembrane helices 2 and 7 of the Î±2A-adrenoceptor restore agonist activation of Gi1Î±. Cellular Signalling, 2002, 14, 139-144.	3.6	8
378	Engineering a V2 Vasopressin Receptor Agonist- and Regulator of G-Protein-Signaling-Sensitive G Protein. Analytical Biochemistry, 2002, 300, 212-220.	2.4	8

#	Article	IF	Citations
379	Selectivity in the oligomerisation of G protein-coupled receptors. Seminars in Cell and Developmental Biology, 2004, 15, 263-268.	5.0	8
380	Structureâ€“Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. Journal of Medicinal Chemistry, 2020, 63, 3577-3595.	6.4	8
381	Chemogenetic Approaches to Explore the Functions of Free Fatty Acid Receptor 2. Trends in Pharmacological Sciences, 2021, 42, 191-202.	8.7	8
382	G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes. ACS Pharmacology and Translational Science, 2021, 4, 1835-1848.	4.9	8
383	Muscarinic Acetylcholine Receptors in Neuroblastoma Cells: Lack of Effect of Veratrum Alkaloids on Receptor Number. Journal of Neurochemistry, 1984, 43, 33-41.	3.9	7
384	Concurrent specific immunological detection of both primate and rodent forms of the guanine nucleotide binding protein G11î± following their coexpression. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1222, 369-374.	4.1	7
385	Chapter 16 Activation, cellular redistribution and enhanced degradation of the G proteins Gqs and G11 by endogenously expressed and transfected phospholipase C-coupled muscarinic m1 acetylcholine receptors. Progress in Brain Research, 1996, 109, 181-187.	1.4	7
386	Constitutive Activity of GPR40/FFA1. Methods in Enzymology, 2010, 484, 569-590.	1.0	7
387	The Role of miRNA in Stem Cell Pluripotency and Commitment to the Vascular Endothelial Lineage. Microcirculation, 2012, 19, 196-207.	1.8	7
388	The effect of sodium channel activators on muscarinic receptors of neuroblastoma cells. FEBS Letters, 1982, 148, 39-43.	2.8	6
389	Increased concentrations of proteins Gi1 and Gi2 in adipocytes from aged rats alter the sensitivity of adenylyl cyclase to inhibitory and stimulatory agonists. Metabolism: Clinical and Experimental, 1995, 44, 239-244.	3.4	6
390	The Use of Receptor G-Protein Fusion Proteins for the Study of Ligand Activity. Receptors and Channels, 2002, 8, 309-317.	1.1	6
391	Chapter 10 Heteroâ€Oligomerization of Chemokine Receptors. Methods in Enzymology, 2009, 461, 207-225.	1.0	6
392	Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 2010, 432, 575-599.	3.7	6
393	Approaches to Characterize and Quantify Oligomerization of GPCRs. Methods in Molecular Biology, 2015, 1335, 95-105.	0.9	6
394	The Use of Biochemical Methods for Estimating Membrane Potential. Progress in Brain Research, 1982, 55, 321-329.	1.4	5
395	Reduction in accumulation of [3H]triphenylmethylphosphonium cation in neuroblastoma cells caused by optical probes of membrane potential. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 762, 585-592.	4.1	5
396	Effects of prolonged treatment of adipocytes with PGE1, N6-phenylisopropyl adenosine and nicotinic acid on G-proteins and antilipolytic sensitivity. Biochemical Society Transactions, 1991, 19, 212S-212S.	3.4	5

#	Article	IF	Citations
397	Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Bailliere's Clinical Endocrinology and Metabolism, 1996, 10, 177-187.	1.0	5
398	Chapter 24. Oligomerisation of G protein-coupled receptors. Annual Reports in Medicinal Chemistry, 2000, 35, 271-279.	0.9	5
399	Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. Biochemical Journal, 2000, 346, 711.	3.7	5
400	Regulation of the avidity of ternary complexes containing the human 5-HT1Areceptor by mutation of a receptor contact site on the interacting G protein Î± subunit. British Journal of Pharmacology, 2002, 137, 345-352.	5.4	5
401	Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi Î±-subunits. European Journal of Pharmacology, 2004, 499, 91-98.	3.5	5
402	Capillary Electrophoresis Assay for G Protein-Coupled Receptor-Mediated GTPase Activity. Analytical Chemistry, 2007, 79, 1158-1163.	6.5	5
403	An arginine residue is the site of receptor-stimulated, cholera toxin-catalysed ADP-ribosylation of pertussis toxin-sensitive G-proteins. Cellular Signalling, 1993, 5, 485-493.	3.6	4
404	Cyclic AMP differentially regulates the expression of the Î±-subunits of Gs, Gq and G11 G-proteins and their mRNA levels in rat C6 glioma cells. Biochemical Society Transactions, 1995, 23, 10S-10S.	3.4	4
405	Palmitoylation negative mutants of murine G11Î± have decreased ability to interact with the plasma membrane when expressed in COS-1 cells. Biochemical Society Transactions, 1995, 23, 9S-9S.	3.4	4
406	Regulation of cellular Gs? levels and basal adenylyl cyclase activity by expression of the ?2-adrenoceptor in neuroblastoma cell lines. Molecular and Cellular Biochemistry, 1995, 149-150, 213-216.	3.1	4
407	Isolation and characterization of a novel human RGS mutant displaying gain-of-function activity. Cellular Signalling, 2008, 20, 323-336.	3.6	4
408	The First 50 Years of Molecular Pharmacology. Molecular Pharmacology, 2015, 88, 139-140.	2.3	4
409	M3 muscarinic acetylcholine receptor facilitates the endocytosis of mu opioid receptor mediated by morphine independently of the formation of heteromeric complexes. Cellular Signalling, 2017, 35, 208-222.	3.6	4
410	The M ₁ muscarinic receptor is present in situ as a ligand-regulated mixture of monomers and oligomeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	4
411	G-proteins and second messengers in mitogenesis. Progress in Growth Factor Research, 1989, 1, 161-177.	1.6	3
412	Characterization of heterotrimeric G-proteins in adult Acanthocheilonema viteae. Biochemical Journal, 1996, 320, 459-466.	3.7	3
413	Adenylyl cyclase isoform-specific signaling of GPCRs. , 0, , 189-216.		3
414	Fatty airways: a source of good and bad fats?. European Respiratory Journal, 2019, 54, 1902060.	6.7	3

#	Article	IF	Citations
415	Down-regulation of the Î±-subunits of Gi subtypes by prolonged incubation of adipocytes with N6-phenylisopropyl adenosine. Biochemical Society Transactions, 1990, 18, 487-487.	3.4	2
416	Phosphorylation of Gi in intact cells. Trends in Biochemical Sciences, 1990, 15, 13.	7.5	2
417	Identification and Analysis of Function of Heterotrimeric Guanine Nucleotide-Binding Proteins Expressed in Neural Tissue. , 1992, , 1-56.		2
418	Activation of the gonadotropin releasing hormone receptor of Î±T3 cells results in downregulation of the Î± subunits of both Gq/G11. Biochemical Society Transactions, 1993, 21, 498S-498S.	3.4	2
419	Receptor availability defines the extent of agonist-mediated G-protein down-regulation in neuroblastoma Ã— glioma hybrid cells transfected to express the Î²2-adrenoceptor. FEBS Letters, 1994, 355, 166-170.	2.8	2
420	Agonist-Mediated Turnover of G-Protein Î±-Subunit Palmitoyl Groups: Role in Membrane Insertion. , 1998, 88, 241-248.		2
421	G protein-coupled receptors: oligomerisation and association with accessory proteins. Seminars in Cell and Developmental Biology, 2004, 15, 261.	5.0	2
422	Time-resolved FRET approaches to study GPCR complexes. , 0, , 67-89.		2
423	The Use of Spatial Intensity Distribution Analysis to Examine G Protein-Coupled Receptor Oligomerization. , 2017, , 15-38.		2
424	Structureâ€Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. ChemMedChem, 2021, 16, 3326-3341.	3.2	2
425	Defining the Functional Equivalence of Wild-Type and Chemically Engineered G Protein-Coupled Receptors. Neuromethods, 2015, , 1-28.	0.3	2
426	Free fatty acid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
427	The use of receptor G-protein fusion proteins for the study of ligand activity. Receptors and Channels, 2002, 8, 309-17.	1.1	2
428	The use of lipophilic anions to facilitate uptake of triphenylmethylphosphonium cation in membrane-potential studies in neuroblastoma cells. Biochemical Society Transactions, 1982, 10, 375-376.	3.4	1
429	Expression of G-protein Î²-subunit in lean and obese Zucker rats and streptozotocin-induced diabetic and normal rats. Biochemical Society Transactions, 1989, 17, 667-668.	3.4	1
430	Identification and analysis of two distinct isoforms of the guanine nucleotide-binding protein G0 in NG108-15 cells. Biochemical Society Transactions, 1990, 18, 396-399.	3.4	1
431	Agonist activation of transfected human M1 muscarinic acetylcholine receptor in Chinese hamster ovary cells results in concurrent downregulation of GqÎ± and G11Î±. Biochemical Society Transactions, 1993, 21, 497S-497S.	3.4	1
432	Stimulation of p70S6 kinase phosphorylation by the A2A adenosine receptor in primary human endothelial cells and in CHO cells heterologously expressing the receptor. Drug Development Research, 1998, 45, 140-150.	2.9	1

#	Article	IF	Citations
433	Novel approaches to enhance the detection of receptor constitutive activity and inverse agonists. International Congress Series, 2003, 1249, 15-25.	0.2	1
434	Identification and Quantitation of G-Protein Î±-Subunits. , 2004, 259, 207-224.		1
435	The quaternary structure of G protein-coupled receptors. FEBS Journal, 2005, 272, 2913-2913.	4.7	1
436	Functional Complementation and the Analysis of GPCR Dimerization. Contemporary Clinical Neuroscience, 2005, , 267-285.	0.3	1
437	17-P003 Discovery of small molecules to control human embryonic stem cell fate. Mechanisms of Development, 2009, 126, S271-S272.	1.7	1
438	GPCR-G protein fusions: Use in functional dimerization analysis. , 2010, , 53-66.		1
439	Novel Assay Technologies for the Discovery of G Protein-Coupled Receptor Drugs. Neuromethods, 2011, , 231-253.	0.3	1
440	THE USE OF SPECIFIC ANTISERA TO STUDY THE DEVELOPMENTAL REGULATION OF GUANINE NUCLEOTIDE BINDING PROTEINS. , 1987, , 415-418.		1
441	U937 cell differentiation: G protein alterations and interaction with the chemotactic peptide receptor. Biochemical Society Transactions, 1991, 19, 98S-98S.	3.4	0
442	Signal transduction in Rat-1 fibroblasts expressing high levels of the Î±2-C10 adrenergic receptor. Biochemical Society Transactions, 1991, 19, 102S-102S.	3.4	0
443	38 Alterations in the levels and function of guanine nucleotide regulatory proteins in Milan hypertensive rats. Journal of Hypertension, 1993, 11, S412.	0.5	0
444	High level expression of mammalian G protein Î± subunit Gq subtypes in Escherichia coli. Biochemical Society Transactions, 1995, 23, 12S-12S.	3.4	0
445	Interaction of the Î²2-adrenoceptor with epitope-tagged GsÎ±in NG108-15 cells. Biochemical Society Transactions, 1995, 23, 7S-7S.	3.4	0
446	Agonist regulation of high affinity [3H] forskolin binding as a measure of GsÎ±- adenylyl cyclase interactions. Biochemical Society Transactions, 1995, 23, 8S-8S.	3.4	0
447	Signalling characteristics of thyrotropin releasing hormone (TRH) receptor isoforms. Biochemical Society Transactions, 1995, 23, 11S-11S.	3.4	0
448	Go1Î± palmitoylation: Its contribution to Î±2C10 adrenoceptor - Go1Î± coupling. Biochemical Society Transactions, 1995, 23, 406S-406S.	3.4	0
449	Internalisation of Wild type and Mutant Î±1B-Adrenergic Receptors. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
450	Diversity in the signaling and regulation of G protein-coupled receptors. Biochemical Society Transactions, 1999, 27, A24-A24.	3.4	0

#	Article	IF	Citations
451	Receptor-GFP Fusion Proteins; A study of Drug Effects on Receptor Internalisation, Trafficking and Expression. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
452	G protein activation and effector regulation by the human 5-HT1A receptor and the Î± subunit of Gi1 fusion proteins. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
453	Cell Cycle Regulation in Rat 1 Fibroblasts Expressing a Murine Delta Opioid Gi Linked Receptor. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
454	Construction and Analysis of Î±2A-Adrenoceptor Gi/GoÎ±-Subunit Fusion Proteins. Biochemical Society Transactions, 1999, 27, A115-A115.	3.4	0
455	Characterisation of Three Subtypes of Rat Thyrotropin Releasing Hormone Receptor. Biochemical Society Transactions, 1999, 27, A115-A115.	3.4	0
456	Activation and Desensitisation of the Thyrotropin-Releasing Hormone Receptor Visualised by Monitoring Cellular Redistribution of a Î²-arrestin-1-Green Fluorescent Protein Fusion Protein. Biochemical Society Transactions, 1999, 27, A118-A118.	3.4	0
457	Analysis of Protein Palmitoylation. , 2002, , 633-640.		0
458	Monitoring Receptor Dimerisation. Medicinal Chemistry Research, 2004, 13, 18-24.	2.4	0
459	Functional studies of isolated GPCR-G protein complexes in the membrane bilayer of lipoprotein particles. , 0, , 32-52.		0
460	Signaling of dopamine receptor homo- and heterooligomers. , 0, , 90-110.		0
461	Functional consequences of chemokine receptor dimerization. , 0, , 111-124.		0
462	Kinetics of GPCR, G protein, and effector activation. , 0, , 145-158.		0
463	G protein-independent and Î² arrestin-dependent GPCR signaling. , 0, , 217-230.		0
464	Assays to read GPCR modulation and signaling. , 0, , 231-246.		0
465	7TM receptor functional selectivity. , 0, , 270-286.		0
466	Using Receptor-G-Protein Chimeras to Screen for Drugs. , 2003, , 619-621.		0
467	Polymorphisms in murine histamine receptor H1 leading to differential cell surface expression influence autoimmune disease progression. FASEB Journal, 2008, 22, 667.2.	0.5	0
468	Expression of Two Isoforms of the Guanine Nucleotide Binding Protein,Go, IN NG108â€“15 Neuroglioma Cells. , 1991, , 221-235.		0

#	Article	IF	Citations
469	The Use of Stably Transfected Cell Lines in the Analysis of Functional Interactions between GoÎ±1 & GiÎ±2 and the Î±2C10 Adrenoceptor. , 1995, , 99-113.		0
470	Identification of stable opioid receptor Go-protein complexes using GTP-binding protein selective antisera. , 1995, , 87-98.		0
471	Regulation of cellular GsÎ± levels and basal adenylyl cyclase activity by expression of the Î²2-adrenoceptor in neuroblastoma cell lines. , 1995, , 213-216.		0
472	Mechanism of Gonadotrophin Releasing Hormone Receptor Mediated Regulation of G-Proteins in Clonal Pituitary Gonadotrophs. , 1996, , 193-201.		0